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Purpose: Effect of recombinant human growth hormone
(rhGH) administration on lipid storage, and its subsequent
effect on insulin sensitivity have not yet been adequately
examined. Thus, we investigated the effects of rhGH treatment
on muscle triglyceride (TG) and ceramide content, and insulin
sensitivity after 4 weeks of rhGH administration in rats.
Materials and Methods: Fourteen rats were randomly assigned
to two groups: rhGH injection group (GH, n = 7) and saline
injection group (CON, n = 7). GH received rhGH by sub-
cutaneous injections (130 g·kg μ
-1·day
-1, 6 days·week
-1) for 4
weeks, while CON received saline injections that were
equivalent in volume to GH group. Intramuscular TG and
ceramide content and hepatic TG content were measured. To
determine insulin sesitivity, oral glucose tolerance test (OGTT)
and muscle incubation for glucose transport rate were
performed in rats, and used as indicators of insulin sensitivity.
We also examined plasm lipid profiles. Results: After 4 weeks
of rhGH treatment, the GH group had higher muscle and liver
TG contents than the CON (p < 0.05). Ceramide content in GH
was significantly greater than that in CON (p < 0.05). GH also
had higher plasma levels of FFA (p < 0.05), glucose and
insulin responses during OGTT (p < 0.05), and lower glucose
transport rates in submaximal insulin concentration (p < 0.05)
as compared with CON. Results indicate that rhGH treatment
is associated with insulin resistance in rats. Conclusion: rhGH
treatment elevated muscle TG and ceramide content, and
hepatic TG content. Thus, elevation of these compounde by
rhGH treatment could contribute to the development of insulin
resistance in rats.
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INTRODUCTION
The recombinant human growth hormone
(rhGH) has been developed for adults with growth
hormone deficiency (GHD), and its physiological
and therapeutic effects are well documented in the
literature.
1-3 Notably, administration of rhGH is
reported to antagonize the effects of insulin on
lipid and glucose metabolism;
4-9 in vivo studies
demonstrate that rhGH administration can reduce
insulin and glucose responses in rats.
5,8,10,11
The mechanism responsible for the observed
association between rhGH and insulin resistance
is not well understood, but increased levels of
free fatty acid (FFA) and reduced levels of GLUT-
4 protein molecules have been implicated.
12-17
Another plausible mechanism for insulin resis-
tance is that elevated FFA levels can enhance the
accumulation of intramuscular triglyceride (TG)
content, which may contribute to insulin resis-
tance in skeletal muscle. Some investigators have
shown an inverse association between intramus-
cular TG content and insulin sensitivity.
18,19
However, little is known about this association
after rhGH treatment. Therefore, we investigated
the effects of chronic in vitro rhGH administration
and hypothesized that it will increase intramus-
cular TG content and reduce insulin sensitivity.
The results from this study support that hypo-
thesis.
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MATERIALS AND METHODS
Animals
Fourteen 4-week-old Sprague-Dawley male rats
(Samtaco Bio Korea, Inc; body weight 128.5 ± 3 g)
were housed one per cage in a 12 : 12 light-dark
cycle at 24°C, and were given Harlan rat chow
(Harlan Teklad) with tap water ad libitum. After
7 days of adaptation to the laboratory environ-
ment, the rats were randomly assigned to two
groups: 1) saline injection group (CON, n = 7) and
2) rhGH injection group (GH, n =7). The GH group
received rhGH (Eutropin , LG inc, Gyeonggi,
Korea) by subcutaneous injections (130 g· μ kg
-1·
day
-1, 6 days· week
-1) for 4 weeks, while the CON
group received saline injections as equivalent
volume as the GH group. All protocols were
approved by the Kyungpook National University
Animal Care and Use Committee.
Oral glucose tolerance test (OGTT)
After 4 weeks of treatment and following a 12
hours fast, the rats were given 50% aqueous
glucose solution (1 g· kg
-1 body weight) using a
stomach tube. The rats were placed in acrylic
restrainers on a heating pad, and approximately
0.5 mL of blood was taken from the tail imme-
diately prior to glucose administration, and at 30
and 60 minutes after administration. To determine
plasma insulin levels, blood samples were placed
in microcentrifuge tubes (Cole-parmer internatio-
nal, Vernon hills, IL, USA) containing 30 L Heparin μ
(Choongwae Pharma. Co., Jeonbuk, Korea), and
centrifuged at 10,000 g for 20 minutes. The plasma
portion was removed and stored at - 80°C until
further analysis. Insulin resistance was deter-
mined under submaximal insulin concentrations
during muscle incubation.
Tissue sampling
One week after the OGTT, the rats were fasted
for 8hours and then anesthetized by intraperitoneal
injection with sodium pentobarbital (6.5 mg· kg
-1).
The epitrochlearis muscles were surgically isolated
and removed to assess glucose transport rate in
muscle,
20 while the liver and plantaris muscle were
excised to assay the TG content. Blood samples
were drawn from an abdominal aorta to measure
plasma glucose, insulin, total cholesterol, trigly-
ceride (TG), high-density lipoprotein cholesterol
(HDL-C), and FFA levels.
Determination of glucose transport in skeletal
muscle
Glucose transport activity was measured using
3-MG (3-O-[
3H]-methylglucose). After dissection,
muscles were rinsed briefly in 25-mL flasks
containing 3 mL of KHB (Krebs-Henseleit buffer,
0.1% BSA) and then transferred to recovery vials
with a recovery medium (32 mM mannitol, 8 mM
glucose). Following this 30 minutes recovery
period, the muscles were transferred to pre-incuba-
tion vials, containing KHB as a preincubation
medium (8 mM glucose, 32 mM mannitol, and
0.1% BSA), and then incubated for 20 minutes.
After 20 minutes of pre-incubation, the muscles
were rinsed with fresh KHB medium-supplement
(40 mM mannitol) and transferred to final incuba-
tion vials. The final incubation medium contained
3-O-[
3H]-methylglucose (2.2 Ci· μ mmol
-1) and [
14C]
mannitol (0.2 Ci· μ mmol
-1) in the presence or
absence of a submaximal (1,000 IU· μ mL
-1) dose of
insulin. Throughout the incubation process, samples
were maintained at 35°C during the recovery and
pre-incubation periods; at 30°C during the rinse;
at final incubation in a shaking water bath (120
cycles· min
-1); and at gassed with a 95% O2 and 5%
CO2 mixture. The muscles were then blotted,
clamp-frozen, and processed for determination of
intracellular 3-MG accumulation and extracellular
space. To determine glucose transport rate, muscle
samples were analyzed in a liquid scintillation
counter (Beckman Instruments, Inc, Fullerton, CA,
USA) by setting the channels at simultaneous
3H
and
14C readings.
21
Determination of GLUT-4 in skeletal muscle
Portions of gasrtrocnemius muscle were homo-
genized for 15 seconds in ice-cold HES buffer (20
mM HEPES, 1 mM EDTA, and 250 mM sucrose),
using a motor driven homogenizer (Art-Miccra D-8
Model, Art Labortechnik, Müllhein, Germany).
Sample homogenates and standards were dilutedMi Jung Park, et al.
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by 1 : 2 with 2x Laemmli sample buffer (S3401,
Sigma-Aldrich, St. Louis, MO, USA) and incubated
for 20 minutes. Muscle homogenates, which con-
tained 50 g of protein, were μ then subjected to SDS-
polyacrylamide-gel-electrophoresis under reducing
conditions of a 10% resolving gel. Resolved pro-
teins were transferred to a nitrocellulose membrane
(BioRad, Hercules, CA, USA) and blocked for 60
minutes with 5% non-fat milk. Membranes were
incubated with GLUT-4 antiserum (Santa Cruz
Biotechology, Santa cruz, CA, USA), diluted with
1 : 10,000 in a T-TBS/5% dry milk, for 90 minutes.
Membrane were washed with T-TBS and incubated
with secondary antibody (ZYMED Labolatories; at
a dilution of 1 : 5000 with T-TBS/1% non-fat milk)
for 60 minutes at room temperature, and washed
with T-TBS. The GLUT-4 protein was visualized
by Hyperfilm (Eastman Kodak, Rochester, NY,
USA) using the Western blot luminal reagent
(Santa Cruz Biotechology, Santa cruz, CA, USA).
Determination of ceramide in skeletal muscle
Plantaris muscles were homogenized in buffer
(0.25 M sucrose, 25 mM KC1, 50 mM Tris, 0.5
mM EDTA; pH7.4). After homogenization, lipid
was extracted by adding a chloroform, methanol,
and buffer water mixture maintained at the ratio
of 0.5:1.0:0.4 and 1.0:1.0:0.9 (v/v/v) before and
after dilution, respectively. Lipid extraction and
ceramide determination were carried out accor-
ding to the guidelines described by Bielawaka et
al.
22
TG contents in muscle and liver
Liver samples were homogenized in 50 mM
potassium phosphate and 1 mM EDTA (pH 7.4)
with 1: 15 dilution, while plantaris muscle samples
were homogenized as 1 : 20 dilution. Lipid was
determined by following guidelines described by
Burton and Anderson.
23 Homongenized samples
were centrifuged at 1,000 g for 10 minutes, and
the supernatant was removed by adding 0.5 mL
of 2-propanol to prevent any evaporation of TG.
The TG content was measured using an enzy-
matic method (Elitech, Sees, France) and quanti-
fied in the skeletal muscle of both groups.
Biochemical measurements
Plasma glucose concentrations were determined
by a glucose analyzer (Model YSI-23A, Yellow
Springs Instruments, Yellow Springs, OH, USA).
Plasma insulin and leptin concentrations were
measured via radioimmunoassay (Linco Research
Inc., St. Louis, MO, USA) by using a double
antibody procedure.
24 Plasma TC, TG, and HDL-C
levels were measured by an enzymatic method
(Elitech, Sees, France). Plasma FFA was deter-
mined by an acyl-CoA oxidase-based colorimetric
kit.
25
Statistical analysis
Independent t tests were used to compare mean
differences for FFA levels, GLUT-4 contents, TG
contents, and glucose transport rates between the
GH and CON groups. Two-way ANOVA with
repeated measures were used to determine plasma
glucose and insulin responses across group by
time factor. The sphericity assumption was justi-
fied using Hyunh-Feldt Epsilon ( ) test. Pearson ε
correlation with simple regression was used to
investigate the association between TG content and
glucose transport rate. All statistical procedures
were performed by SPSS (ver. 14) with a signifi-
cance level at 0.05.
RESULTS
Growth rate
There was no statistical difference in growth rate
between the GH and CON groups (Fig. 1).
Biochemical characteristics
Biochemical characteristics after 4 weeks of
rhGH treatments are presented in Table 1. The GH
group (0.83 ± 0.07 mmol· L
-1) had higher FFA
values than the CON group did (0.58 ± 0.05 mmol·
L
-1, p < 0.05). There were no statistical differences
in TC, TG, and HDL-C values between the 2
groups.hGH Administration on Insulin Resistance of Skeletal Muscle
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Oral glucose tolerance test
As shown in Fig. 2, the GH group had higher
glucose levels than the CON group at basal time
(GH 132.6 ± 5.0 vs CON 98.9 ± 4.5 mg· dL
-1, p <
0.05) and at 60 minutes (GH 182.0 ± 13.2 vs CON
148.7.90 ± 6.1 mg· dL
-1, p < 0.05) as compared with
the CON group, respectively. The GH group also
had higher insulin levels at basal time (GH 1.95
± 0.36 vs CON 0.98 ± 0.07 U· μ mL
-1, p < 0.05), at 30
minutes (GH 4.53 ± 0.42 vs CON 2.54 ± 0.35 U· μ
mL
-1, p < 0.05), and at 60 minutes (GH 3.62 ± 0.21
vs CON 1.81 ± 0.21 U· μ mL
-1, p < 0.05) as compared
with the CON group, respectively.
GLUT-4 contents in muscle
There was no statistical difference in GLUT-4
contents between the GH (RG: 37.7 ± 2.0%, WG:
21.3 ± 1.5%) and CON (RG: 36.6 ± 2.3%, WG: 22.3
± 1.6%) groups (Fig. 3).
Table 1. Biochemical Characteristics after 4 Weeks of rhGH Treatments
Variables GH (n = 7) CON (n = 7)
FFA (mmol/L) 0.88 ± 0.1* 0.59 ± 0.1
TC (mg/dL) 84.2 ± 2.2 79.7 ± 2.2
TG (mg/dL) 40.1 ± 3.2 34.1 ± 3.4
HDL-C (mg/dL) 33.4 ± 1.8 30.4 ± 1.4
CON, saline injection group, GH; rhGH injection group; FFA, free fatty acid; TC, total cholesterol; TG, triglyceride; HDL-C,
high-density lipoprotein cholesterol.
Values are presented as the mean ± SE.
*p < 0.05.
Fig. 2. Effect of growth hormone administration on plasma glucose (A) and insulin (B) concentrations during OGTT. CON,
control group; GH, growth hormone group; OGTT, oral glucose tolerance test. Each point represents the mean ± SE.
*p < 0.05.
Fig. 1. Change in body weight over 2-day intervals. CON,
control group; GH, growth hormone group.
A BMi Jung Park, et al.
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TG contents in muscle and liver
Fig. 4 shows that the GH group (1.56 ±0.12 mol μ
· g
-1) had greater TG content in the plantaris
muscle compared with the CON group (0.79 ± 0.08
mol μ · g
-1, p < 0.05). The GH group also had signifi-
cantly higher TG content in the liver (9.29 ± 1.46
mol· g μ
-1) than with the CON group (5.12 ± 0.59
mol· g μ
-1, p < 0.05).
Ceramide contents in muscle
Fig. 5 shows that the GH group (83.8 ± 2.1 pmol
· mg
-1) had greater ceramide content in the skeletal
muscle than with the CON group (75.7 ± 2.7 pmol·
mg
-1, p < 0.05).
Glucose transport rate in muscle
As shown in Fig. 6, the GH group had a lower
glucose transport rate under submaximal insulin
concentrations (2.36 ± 0.18 mol· μ mL
-1· hr
-1) than the
CON group (3.26 ± 0.26 moL· μ mL
-1· hr
-1, p < 0.05).
However, there was no statistical difference
between these 2 groups under non-insulin condi-
tions.
Fig. 3. GLUT-4 contents in red garstrocnemius (RG) (A) and white garstrocnemius (WG) (B) muscle. CON, control group;
GH, growth hormone group. Each point represents the mean ± SE.
Fig. 4. Triglyceride contents in plantaris muscle (A) and liver (B). CON, control group; GH, growth hormone group. Each
point represents the mean ± SE. *p < 0.05.
A B
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Triglyceride content and glucose transport rate
Fig. 7 shows the association between glucose
transport rate and muscle TG content. There was
a significant inverse association between muscle
TG content and glucose transport rate (r = - 0.67,
p < 0.01).
DISCUSSION
In the present study, we observed a decrease in
plasma glucose and insulin responses during
OGTT and glucose transport rate during muscle
incubation under submaximal insulin concentra-
tion in rhGH injected rats (130 g· μ kg
-1· day
-1 for 4
weeks). Also, we observerd that prolonged expo-
sure to rhGH elevated intramuscular TG and
ceramide levels in rats. In addition, plasma FFA
and hepatic TG content were also elevated when
rhGH was administered. Thus, the major finding
of this study is that the decreased insulin sensi-
tivity due to chronic rhGH administration would
partly result from an elevated intramuscular cera-
mide content which is deriveded from the elevated
muscle TG content.
It has been reported that there was an inverse
relationship between insulin sensitivity and intra-
muscular TG stroage,
19,26 similar to the results of
the present study. However, elevated intramus-
cular TG storage in itself did not reduce muscle
insulin sensitivity, but rather acts as a source for
Fig. 6. Glucose transport rate in epitrochlearis muscle with
non- (B) and submaximal insulin conditions (A). CON,
control group; GH, growth hormone group. Each point
represents the mean ± SE. *p < 0.05.
Fig. 7. Correlation between glucose transport rate and
muscle TG content under submaximal insulin concentra-
tions. TG, triglyceride.
Fig. 5. Ceramide contents in garstrocnemius muscle . CON,
control group; GH, growth hormone group. Each point
represents the mean ± SE. *p < 0.05.
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lipid derivatives, such as diacylgycerol, long chain
fatty acid acyl-CoA or ceramides, that directly
affect insulin signalling and, thus, insulin sensiti-
vity.
27-29 In previous studies,
27 these was a possi-
bility that ceramide might inhibit insulin sig-
nalling at the level of protein kinase B (PKB)/
Akt.
30 Therefore, we hypothesized that the de-
creased glucose transport due to rhGH injection
might partly result from elevations of intramus-
cular TG storage and ceramide content. In the
current investigation, we observed that rhGH
administation significantly elevated muscle TG
storage and ceramide content. Thus, intramuscular
ceramide elevation due to rhGH injection may
partly contribute to the development of insulin
resistance
It has also been postulated that FFA levels due
to rhGH treatment are responsible for insulin
resistance.
31,32 The elevated FFA levels demon-
strated here is consistent with previous reports.
16,
33 Many previous studies reported that an increase
in circulating FFA is a key factor for the develop-
ment of insulin resistance in insulin sensitive
tissues such as adipocytes and skeletal muscle.
13,34,35 Increased level of FFA by rhGH treatment
has been suggested to be related to insulin resis-
tance.
14,16,36 In vitro studies have indicated that the
lipolytic actions of rhGH may involve stimulation
of gene expression after binding to the rhGH
receptor and subsequent activation of JAK2
tyrosine kinase, adenyl cyclase, and stimulation of
cAMP production, triggering the hormone-sensi-
tive lipase by increasing circulating FFA.
37-39
According to the glucose-FFA cycle postulated by
Randle et al.,
40 increased FFA concentrations may
decrease the uptake of glucose in skeletal muscle.
Skeletal muscle is responsible for 70 - 80% of whole
body insulin-stimulated glucose uptake and is,
therefore, considered to be the most important site
of insulin resistance.
13 The mechanism by which
raised plasma FFA concentrations inhibit insulin-
stimulated glucose uptake in muscle may involve
the insulin-signaling pathway responsible for
GLUT4 translocation, including IRS-1 phosphory-
lation, PI3K activity, or glycogen synthase activity.
41-44 In addition, an inverse correlation between
muscle lipid content and insulin sensitivity has
been demonstrated in humans by muscle biopsy,
19
computed tomography
45 and magnetic resonance
spectroscopy.
26 TG stored within the muscle fiber
has been implicated as a casual factor in the insulin
resistance-FFA relationship, and the postulated
mechanism involves intramyocellular accumula-
tion of diacylglycerol, activation of protein kinase
C, or myoplasmic long-chain fatty acyl CoA.
46,47
We also observed that GLUT-4 protein levels
were similar between the GH and CON groups.
GLUT-4 is the major glucose transporter protein
in skeletal muscle, and the muscle GLUT-4 protein
levels are significantly related to the rate of glucose
transport during muscle incubation.
48 Therefore,
any decrease in the rate of glucose transport in
rhGH-treated rats would seem to require a reduc-
tion of GLUT-4 levels in skeletal muscle. However,
our data showed no reduction of muscle GLUT-4
protein levels in the rhGH-treated rats, and sug-
gest that the deflect in the signalling mechanism
occurred prior to the glucose translocation process.
This result is consistent with the previous reports
that muscle GLUT-4 protein levels were not
altered in rhGH-treated rats,
10,41 and supports the
concept that alterations of muscle GLUT-4 protein
levels are not responsible for the reduction of
insulin-stimulated glucose disposal in rhGH-
treated rats.
It is plausible that rhGH-treated rats develop
insulin resistance in skeletal muscle due to
elevated intramuscular TG storage and ceramide
content. Elevation of circulating FFA levels due to
rhGH treatment enhances intramuscular TG
content, and high levels of muscle TG and cera-
mide content are responsible for insulin sensitivity
in skeletal muscle. Our data also showed that
reduced glucose transport rate in the rhGH-treated
rats occurred with no change in GLUT-4 content,
and was directly related to the TG content of the
muscle. A strength of this study is that, to our
knowledge, this is the first study to specifically
investigate the association between muscle TG
content and glucose transport rate after the rhGH
treatment. Our study is also well designed to
eliminate all possible confounding factors using a
randomized control design. Further studies are
needed to validate our findings across different
murines as well as in humans.
In conclusion, we found that rhGH treatment is
directly associated with insulin resistance in rats.
The causative factor for insulin resistance is thathGH Administration on Insulin Resistance of Skeletal Muscle
Yonsei Med J Vol. 49, No. 6, 2008
rhGH treatment elevates TG content and ceramide
in muscle, and an elevated TG and ceramide
contents are inversely associated with insulin sen-
sitivity in rats.
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